Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company with no product revenue, built around deramiocel, an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy, plus an earlier-stage exosome platform. In Friday's session the shares traded at $7.94, up $0.41 or 5.44% from the prior close of $7.53, confirming a move to the upside. The advance came without any new corporate announcement or data release. It is best explained as a rebound from a sharp six-session selloff combined with pre-decision positioning ahead of the FDA's Nov. 22 action date on the deramiocel biologics license application.
The single fact dominating the tape is the Nov. 22 target action date on Capricor's BLA for deramiocel. The agency extended the deadline by three months from Aug. 22 after the company submitted a roughly 30,000-page major amendment containing 24-month open-label extension data from the Phase 3 HOPE-3 trial, more than 900 robustness re-analyses, and an integrated summary of efficacy combining HOPE-2 and HOPE-3. Capricor also narrowed its proposed indication to upper-limb impairment in patients aged nine and older, the population in which HOPE-3 met its primary endpoint with a 1.1-point benefit on the PUL 2.0 scale at a p-value of 0.029.
That framing matters because the advisory committee's 9-3 vote in July addressed the cardiomyopathy indication, not the upper-limb endpoint. With the decision landing on a weekend, action could arrive after Friday's close or at the start of next week, and traders have historically added exposure into such deadlines rather than ahead of them. Approval would validate the first therapy specifically targeting upper-limb function in Duchenne; a second complete response letter would leave a company with no revenue and roughly $198.5 million in cash as of Sept. 30 to regroup.
Today's gain is also the arithmetic mirror of the preceding decline. After surging 26.5% on Nov. 11, when Jones Trading upgraded the stock to Buy with a $25 target, the shares fell in six consecutive sessions from $11.22 to $7.53, a decline of about 33%. That slide came despite Roth Capital lifting its target to $10.50 from $7.00 on Nov. 13 while keeping a Neutral rating, a reminder that published targets on the name span an unusually wide $7 to $54 range. A 5% bounce after a one-third drawdown in a stock with a 0.77 five-year beta and a small float is consistent with routine mean reversion rather than a change in fundamentals.
Participation has been heavy: Thursday's volume of more than 7.9 million shares was well above the roughly 4.7 million-share average, and the Nov. 11 session traded over 6 million. Today's advance is a single-stock story rather than a sector one, and the shares remain more than 80% below their 52-week high of $40.37 and roughly 30% below the Nov. 11 close. Technically, the stock is attempting to reclaim ground lost during the slide, having closed Thursday near the bottom of a wide $7.38-to-$9.12 range. Market capitalization stands at approximately $460 million.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 14 out of 100. No verified news was released before the move; the relevant fundamental backdrop is a scheduled regulatory deadline already public for months, so the news component is weak relative to the company's size. The price component is equally muted: today's 5.44% gain is almost exactly the stock's average absolute daily move of roughly 5.5% over the past 60 sessions, and 22 of those sessions produced moves of similar or greater size. Two ordinary components combine into a low score.
Attention is fixed on the FDA's decision, expected imminently around the Nov. 22 date. Beyond the headline, investors will parse the approved label for how broadly the eligible population is defined, since that determines launch reach. Capricor has said its San Diego facility is operational for initial supply, with capacity expansion targeted for 2027, and that approval could bring a transferable Rare Pediatric Disease Priority Review Voucher, a potential source of non-dilutive capital. The company has also flagged a contractual dispute with NS Pharma over distribution rights, with an arbitration hearing expected in the middle of 2027, and final Phase 1 StealthX vaccine data anticipated in the first half of 2027. With a $42.7 million quarterly net loss and a 10% workforce reduction already in place, funding and execution risk remain live regardless of the decision.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are gathered in one curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as conditions change. The Trending AI Robots page is a practical starting point for comparing live strategies before deciding which approaches deserve closer attention.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day RSI Oscillator for CAPR moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 68 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.596). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology